, Tracking Stock Market Picks
Enter Symbol:
Avanir Pharmaceuticals (AVNR) [hlAlert]

Mkt Outperform
up 557.36 %

Avanir Pharmaceuticals (AVNR) rated Mkt Outperform with price target $7 by JMP Securities

Posted on: Tuesday,  Aug 23, 2011  10:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Avanir Pharmaceuticals (NASDAQ: AVNR) on 08/23/2011, when the stock price was $2.58.
Since then, Avanir Pharmaceuticals has gained 557.36% as of 01/12/2015's recent price of $16.96.
If you would have followed this JMP Securities's recommendation on AVNR, you would have gained 557.36% of your investment in 1238 days.

Avanir Pharmaceuticals is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Company?s product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The Company?s first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA).

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/23/2011 10:25 AM Buy
2.58 7.00
as of 12/30/2011
1 Week up  10.81 %
1 Month down  -16.66 %
3 Months down  -28.32 %
1 YTD down  -20.54 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy